NO20072747L - Process for the preparation of indazole compounds - Google Patents

Process for the preparation of indazole compounds

Info

Publication number
NO20072747L
NO20072747L NO20072747A NO20072747A NO20072747L NO 20072747 L NO20072747 L NO 20072747L NO 20072747 A NO20072747 A NO 20072747A NO 20072747 A NO20072747 A NO 20072747A NO 20072747 L NO20072747 L NO 20072747L
Authority
NO
Norway
Prior art keywords
preparation
compounds
formula
indazole compounds
protein kinases
Prior art date
Application number
NO20072747A
Other languages
Norwegian (no)
Inventor
Bing Shi
Qingping Tian
Babu Srinivasan
Jr Raymond Dagnino
Michael Allen Ouelette
Scott Edward Zook
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20072747L publication Critical patent/NO20072747L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Foreliggende oppfinnelsen angår fremgangsmåter for fremstilling av indasolforbindelser som har formel (I) eller farmasøytisk akseptable salter eller solvater derav. Forbindelser med formel (I) er anvendelige som antiangiogenesemidler og som midler for å modulere og/eller inhibere aktiviteten til proteinkinaser, som således tilveiebringer behandlinger for kreft eller andre sykdommer assosiert med cellulær proliferasjon mediert av proteinkinaser.The present invention relates to processes for the preparation of indasol compounds having formula (I) or pharmaceutically acceptable salts or solvates thereof. Compounds of formula (I) are useful as antiangiogenic agents and as agents for modulating and / or inhibiting the activity of protein kinases, thus providing treatments for cancer or other diseases associated with cellular proliferation mediated by protein kinases.

NO20072747A 2004-11-02 2007-05-30 Process for the preparation of indazole compounds NO20072747L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62457504P 2004-11-02 2004-11-02
PCT/IB2005/003300 WO2006048745A1 (en) 2004-11-02 2005-10-21 Methods for preparing indazole compounds

Publications (1)

Publication Number Publication Date
NO20072747L true NO20072747L (en) 2007-07-31

Family

ID=35528034

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072747A NO20072747L (en) 2004-11-02 2007-05-30 Process for the preparation of indazole compounds

Country Status (15)

Country Link
EP (1) EP1809625A1 (en)
JP (1) JP2008518901A (en)
KR (1) KR20070058689A (en)
CN (1) CN101044138A (en)
AR (1) AR051753A1 (en)
AU (1) AU2005300311A1 (en)
BR (1) BRPI0517921A (en)
CA (1) CA2586176A1 (en)
IL (1) IL182096A0 (en)
MX (1) MX2007003603A (en)
NO (1) NO20072747L (en)
RU (1) RU2007114112A (en)
TW (1) TW200614990A (en)
WO (1) WO2006048745A1 (en)
ZA (1) ZA200702317B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
EP4249063A3 (en) * 2007-04-05 2024-03-13 Pfizer Products Inc. Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals
EP2214675B1 (en) 2007-10-25 2013-11-20 Genentech, Inc. Process for making thienopyrimidine compounds
EP2163544A1 (en) * 2008-09-16 2010-03-17 Pfizer, Inc. Methods of preparing indazole compounds
TW201328725A (en) 2011-09-30 2013-07-16 Pfizer Pharmaceutical compositions of N-methyl-2-3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl-benzamide
CA2855211A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
CN103387565B (en) * 2013-07-29 2014-10-29 苏州明锐医药科技有限公司 The preparation method of Axitinib
CN103570696B (en) * 2013-11-06 2016-02-24 湖南欧亚生物有限公司 A kind of preparation method of Axitinib intermediate and preparing the application in Axitinib
WO2015067224A1 (en) 2013-11-08 2015-05-14 Zentiva, K.S. Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
SI3102605T1 (en) 2014-02-04 2019-04-30 Pfizer Inc. Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
CN106458920B (en) * 2014-03-31 2019-02-15 千寿制药株式会社 Alkynyl indazole derivatives and their uses
CN104072484B (en) * 2014-07-07 2016-07-06 渤海大学 Nitrogen-(4-(aromatic thiohydroxy)-1 hydrogen-indazole-3-base)-1-(heteroaromatic replacement) methylene imine compounds and pharmaceutically acceptable salt and its preparation method and application thereof
CA2955676A1 (en) 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
BR112017018234A2 (en) 2015-02-26 2018-04-17 Merck Patent Gmbh pd-1 / pd-l1 inhibitors for cancer treatment
US9580406B2 (en) 2015-04-28 2017-02-28 Signa S.A. De C.V. Processes for the preparation of axitinib
RU2766890C2 (en) 2015-06-16 2022-03-16 Мерк Патент Гмбх Combined methods for treating with pd-l1 antagonists
WO2018065938A1 (en) 2016-10-06 2018-04-12 Pfizer Inc. Dosing regimen of avelumab for the treatment of cancer
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
WO2020212253A1 (en) 2019-04-18 2020-10-22 Synthon B.V. Process for preparing axitinib, process for purifying the intermediate 2-((3-iodo-1h-indazol-6-yl)thio)-n-methylbenzamide, process for purifying axitinib via the axitinib hcl salt, solid form of the axitinib hcl salt
CN112209861A (en) * 2019-07-11 2021-01-12 鲁南制药集团股份有限公司 Acixtinib intermediate compound and preparation method thereof
CN112442010B (en) * 2019-08-30 2023-10-03 润佳（苏州）医药科技有限公司 A class of prodrug compounds and their application in treating cancer
CN111440102B (en) * 2020-04-26 2022-02-15 大连凯飞化学股份有限公司 Preparation method of dithiodibenzoamide compound
AU2023227442A1 (en) 2022-03-03 2024-09-12 Pfizer Inc. Multispecific antibodies and uses thereof
CN114591338B (en) * 2022-03-31 2023-05-09 苏州欧康维视生物科技有限公司 Preparation method and application of Syk and VEGFR2 double-target inhibitor
CN119604488A (en) * 2022-08-08 2025-03-11 苏州必扬医药科技有限公司 A protein tyrosine kinase inhibitor and its medical use
WO2025157389A1 (en) 2024-01-22 2025-07-31 Iomx Therapeutics Ag Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20010306A1 (en) * 1999-07-02 2001-03-29 Agouron Pharma INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM USEFUL FOR THE INHIBITION OF PROTEIN KINASE
JP3814285B2 (en) * 2002-12-19 2006-08-23 ファイザー・インク 2- (1H-indazol-6-ylamino) -benzamide compounds as protein kinase inhibitors useful in the treatment of eye diseases
MXPA05009459A (en) * 2003-03-03 2006-05-17 Array Biopharma Inc P38 inhibitors and methods of use thereof.
WO2005094823A1 (en) * 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. Flt-3 INHIBITOR

Also Published As

Publication number Publication date
AR051753A1 (en) 2007-02-07
CA2586176A1 (en) 2006-05-11
CN101044138A (en) 2007-09-26
ZA200702317B (en) 2008-09-25
IL182096A0 (en) 2007-07-24
BRPI0517921A (en) 2008-10-21
TW200614990A (en) 2006-05-16
EP1809625A1 (en) 2007-07-25
WO2006048745A1 (en) 2006-05-11
KR20070058689A (en) 2007-06-08
AU2005300311A1 (en) 2006-05-11
JP2008518901A (en) 2008-06-05
RU2007114112A (en) 2008-12-10
MX2007003603A (en) 2007-05-21

Similar Documents

Publication Publication Date Title
MX2007003603A (en) Methods for preparing indazole compounds.
NO20073140L (en) Pyrrolopyrazines and pyralopyrazines useful as inhibitors of protein kinases
NO20083427L (en) Cystotoxic agents comprising novel tomaymycin derivatives and their therapeutic use
NO20081454L (en) Met kinase inhibitors
NO20090581L (en) Hydroxylated and methoxylated cyclopenta [D] pyrimidines as AKT protein kinase inhibitors
NO20061743L (en) quinazoline
NO20064895L (en) 6,6-Bisyclic ring-substituted heterobicyclic protein kinase inhibitors
NO20061194L (en) Mitotic kinesin inhibitors
NO20083214L (en) Pyrimidinylarylurea derivatives which are converted to FGF inhibitors
TN2009000128A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
NO20070514L (en) Pyrrolotriazine kinase inhibitors
NO20080675L (en) P38-Map kinase inhibitors and methods for their use
NO20061327L (en) quinazoline
NO20075082L (en) Pyridine-3-carboxamide derivatives as CB1 inversion agonists
NO20063449L (en) Substituted heterocycles and their use
YU84603A (en) Novel tyrosine kinase inhibitors
NO20070917L (en) Imidazotriazines as protein kinase inhibitors
EA201070167A1 (en) SUBSTITUTED DERIVATIVES INDAZOLA, ACTIVE AS KINASE INHIBITORS
EA201070618A1 (en) 4-PYRAZOLYL-N-Arylpyrimidine-2-amines and 4-pyrazoyl-N-heteroarylpyrimidine-2-amines as an Inhibitor of Kinase JANUS
NO20081893L (en) 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
NO20062763L (en) Pyrrolotriazine Compounds as Kinase Inhibitors
NO20072461L (en) Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
NO20071619L (en) Process for the preparation of indazole compound
NO20091708L (en) Novel kinase inhibitors
NO20060415L (en) Piperidyl-Kinazoline Derivatives as Tyrosine-Kinase Inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application